Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.65 |
| ▸ | CCND3 | P30281 | 20/20 | 0.65 |
| ▸ | CDK6 | Q00534 | 16/20 | 0.65 |
| ▸ | CDK1 | P06493 | 14/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | CDK7 | P50613 | 1/20 | 0.62 |
| ▸ | CDK9 | P50750 | 1/20 | 0.62 |
| ▸ | CCNH | P51946 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29686496 | 1.00 | CDK4 (0.65) | CDK4CCND3CDK6CDK1CCNA2 | |
| SCHEMBL21499040 | 1.00 | CDK4 (0.65) | CDK4CCND3CDK6CDK1CCNA2 | |
| SCHEMBL18191681 | 0.91 | CDK4 (0.79) | CDK4CCND3CDK6CDK1CCNA2 | |
| SCHEMBL20528183 | 0.91 | CDK4 (0.79) | CDK4CCND3CDK6CDK1CCNA2 | |
| SCHEMBL18191753 | 0.90 | CDK4 (0.70) | CDK4CCND3CDK6CDK1CCNA2 | |
| SCHEMBL29686798 | 0.90 | CDK4 (0.70) | CDK4CCND3CDK6CDK1CCNA2 | |
| SCHEMBL21499013 | 0.89 | CDK4 (0.65) | CDK4CCND3CDK6CDK1CCNA2 | |
| SCHEMBL18191696 | 0.89 | CDK4 (0.65) | CDK4CCND3CDK6CDK1CCNA2 | |
| SCHEMBL29686754 | 0.89 | CDK4 (0.65) | CDK4CCND3CDK6CDK1CCNA2 | |
| SCHEMBL18201881 | 0.88 | CDK4 (0.69) | CDK4CCND3CDK6CDK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288931-B2 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-07-20 | — | — | EP | claimed |
| CN-107849012-B | Kinase inhibitor | 重庆复创医药研究有限公司 | 2021-05-25 | — | — | CN | claimed |
| EP-3288931-B1 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2019-11-06 | — | — | EP | claimed |
| US-10450316-B2 | Certain protein kinase inhibitor | Chongqing Fochon Pharmaceutical Co., Ltd. (CN) | 2019-10-22 | — | — | US | claimed |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | FOCHON BIOSCIENCES, LTD. (CN) | 2018-10-11 | — | — | US | claimed |
| EP-3288931-B2 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| CN-107849012-B | Kinase inhibitor | 重庆复创医药研究有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| EP-3288931-B1 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-10450316-B2 | Certain protein kinase inhibitor | Chongqing Fochon Pharmaceutical Co., Ltd. (CN) | 2019-10-22 | — | — | US | disclosed |
| US-10450316-B2 | Certain protein kinase inhibitor | Chongqing Fochon Pharmaceutical Co., Ltd. (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | FOCHON BIOSCIENCES, LTD. (CN) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450316-B2 | Certain protein kinase inhibitor | CDK4, CDK6, CDK2 | CDK4 1/4885CCND3 96/4885CDK6 2/4885 |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | CDK4 1/4885CCND3 41/4885CDK6 2/4885 |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | CDK4, CDK6, CDK2 | CDK4 1/4885CCND3 242/4885CDK6 2/4885 |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | CDK4, CDK6, CDK1 | CDK4 1/4885CCND3 38/4885CDK6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.